Watch Dr. Goldberg's presentation below regarding localized treatment of cancers in a more safe and effective way and the positive... read more

Privo Technologies, Inc.  attends the BIO International Convention online from June 14-18, 2021. Despite the conference being held online this year... read more

Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research Institute... read more

Peabody, MA -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy... read more

Privo Technologies received the “2015 National Innovation Award” from the TechConnect World Innovation Conference. Privo’s ChemoThin Wafer project was rated... read more

Privo Technologies has been awarded ~$2 million in funding from the FDA through its Office of Orphan Product Development (OOPD)... read more

​​​​​Privo Technologies (Privo) has been selected for the prestigious Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI SBIR... read more

PEABODY, Mass., October 22, 2021 --Privo Technologies, Inc. ("Privo"), announced today the positive results of their Phase 1/2 clinical trial examining... read more

Privo Technologies is honored to receive a Phase 2 award for $2M from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more

The Salisbury Award Competition is a set of competitions participated in by investigators at major cancer research institutions and/or scientists at... read more